Skip to main content
PolyPeptide Group AG logo

PolyPeptide Group AG — Investor Relations & Filings

Ticker · PPGN ISIN · CH1110760852 LEI · 5067007JCKTPOX4G9758 SW Manufacturing
Open in API
Filings indexed 111 across all filing types
Latest filing 2025-03-11 Earnings Release
Country CH Switzerland
Listing SW PPGN

About PolyPeptide Group AG

https://www.polypeptide.com/

PolyPeptide Group AG is a Contract Development & Manufacturing Organization (CDMO) specializing in peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs). The company serves the pharmaceutical and biotech sectors by providing a comprehensive range of services that cover all stages of product development, from pre-clinical to commercial manufacturing. Its offerings include both proprietary (custom) and generic GMP-grade peptides. PolyPeptide focuses on innovation in peptide synthesis and manufacturing processes to support the development of therapies for patients.

Recent filings

Filing Released Lang Actions
PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad-hoc' announcement and a 'Media release – ad hoc announcement pursuant to Art. 53 LR'. It announces the 'annual results for 2024' and provides guidance for 2025, including key financial figures (Revenue, EBITDA, Cash Flow) and strategic updates. This content structure—a summary announcement of yearly financial performance with forward guidance—is characteristic of an Earnings Release (ER). Although it discusses annual results, it is presented as a summary press release, not the comprehensive 10-K filing itself. Furthermore, it mentions the upcoming AGM and a proposed board member nomination, which are secondary details within this primary results announcement. Given the focus on summarizing the full year's financial performance immediately upon release, ER is the most appropriate classification over 10-K (which is the full statutory filing) or MDA (which is typically a more detailed management discussion accompanying the full report). Since it contains the core financial highlights, ER is preferred over RPA. FY 2024
2025-03-11 English
PolyPeptide with substantial improvements in profitability and cash flow, positioned for strong growth
Earnings Release Classification · 100% confidence The document is explicitly titled as an 'Ad hoc announcement' and a 'Media release' announcing the company's 'annual results for 2024'. It provides key financial highlights (Revenue, EBITDA, Cash Flow) and guidance for 2025. While it discusses the 'Annual Report 2024' in a footnote and mentions where to find full documents, the primary nature of this text is the immediate release of summarized annual performance data and forward-looking statements, which aligns best with an Earnings Release (ER). It is not the full 10-K, nor is it merely an announcement of a report (RPA), as it contains substantial summarized results. The mention of board nominations for the upcoming AGM is secondary to the primary financial results announcement. FY 2024
2025-03-11 English
PolyPeptide mit substantiellen Verbesserungen bei Profitabilität und Cashflow, positioniert für starkes Wachstum
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' and contains detailed financial results for the full year 2024 ('Jahresergebnisse für 2024'), including revenue, EBITDA, net income, and cash flow figures compared to 2023. It also provides a forecast for 2025 and discusses strategic capacity expansions. The structure, content (full year financials), and the fact that it is an 'Ad hoc-Mitteilung' (a mandatory disclosure for listed companies) strongly suggest this is the primary annual financial disclosure, which aligns best with the Annual Report (10-K) category, even though it is presented as a press release/ad hoc announcement. Since the document contains the comprehensive annual financial performance data rather than just a brief announcement of results (ER) or a management discussion (MDA), it is classified as the Annual Report (10-K). The document length (23,776 chars) also supports it being a comprehensive report rather than a short announcement (RPA/RNS). FY 2024
2025-03-11 German
Annual Report 2024
Annual Report Classification · 100% confidence The document is a comprehensive annual report for PolyPeptide Group AG for the year 2024. It includes a Management Report, key financial figures, business review, strategy, and references to consolidated financial statements. It is clearly a full-year report rather than an interim or quarterly report, and it contains substantive financial data and management analysis, distinguishing it from a mere announcement or certification. FY 2024
2025-03-10 English
Doubling of production capacity at the manufacturing site in Malmo
Regulatory Filings Classification · 99% confidence The document is a 'Media release' dated January 8, 2025, announcing a specific corporate action: the planned doubling of production capacity at the Malmö manufacturing site. It discusses investment plans (EUR 100 million) and job creation related to fulfilling a large commercial agreement. This type of announcement, detailing operational expansion and strategic execution outside of standard financial reporting (like 10-K or ER), is best classified as a general corporate update. Since it is a news release detailing operational strategy and investment rather than a formal regulatory filing like a Director's Dealing (DIRS) or a Capital/Financing Update (CAP) which usually involves issuing securities or debt, the most appropriate general category for significant corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for important, non-standard announcements disseminated via news services like EQS.
2025-01-09 English
Doubling of production capacity at the manufacturing site in Malmo
Capital/Financing Update Classification · 99% confidence The document is a 'Media release' dated January 8, 2025, announcing a specific corporate action: the planned doubling of production capacity at the Malmö manufacturing site. It discusses investment plans (EUR 100 million) and job creation related to fulfilling a large commercial agreement. This type of announcement, detailing operational expansion and strategic execution outside of standard financial reporting (like 10-K or ER), is best classified as a general corporate update. Since it is a news release detailing operational strategy and investment rather than a formal regulatory filing like a Director's Dealing (DIRS) or a Capital/Financing Update (CAP) which usually involves issuing securities or debt, the most appropriate general category for significant corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for important, non-standard announcements disseminated via news services like EQS.
2025-01-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.